RecruitingPhase 4ACTRN12612000477820

Subcutaneous Frusemide in patients with heart failure

The Use of Continuous Subcutaneous Frusemide in Decompensated Heart Failure: can it achieve a diuresis?

Sponsor

Auckland City Hospital

Enrollment

20 participants

Start Date

May 1, 2012

Study Type

Interventional

Conditions

Decompensated Heart Failure

Summary

The proposed study is a single centre, prospective, feasibility study measuring the effectiveness of continuous sc Frusemide (CSI-F) in achieving a diuresis in patients with decompensated heart failure.Eligible patients with decompensated heart failure who are admitted to Auckland City Hospital will be treated for the first 24 hours with usual therapy (as per Consultant Cardiologist). After 24 hours of usual care, and after obtaining informed consent, patients will receive Frusemide via a continuous subcutaneous infusion.A Safe-T Intima sc cannula will be inserted with an aseptic technique under the skin by the researcher or patients nurse. The infusion dosage will run as per Consultants medical orders via a Niki T34 syringe driver. The dose of Frusemide will be decided by the Cardiology Consultant responsible for the patients care, and will usually be dose for dose that which would be administered IV. Baseline recordings will be taken such as blood pressure (BP), heart rate (HR), respiratory rate (RR), temperature and weight will be taken prior to infusion.Primary outcome measures will be of net urine volume voided, urine sodium concentration, time to first void, weight, breathlessness and peripheral oedema score.Secondary outcome measures will be serum creatinine, site reactions, length of hospital stay, and number of days out of hospital.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study is testing whether a water-removing medication called frusemide (furosemide) can be delivered effectively under the skin (subcutaneously) rather than through a vein (intravenously) in people with worsening heart failure. When the heart is not pumping well, fluid builds up in the body. This study will check whether the under-the-skin method works as well as standard IV treatment at removing excess fluid. You may be eligible if: - You are 18 years of age or older - You have been admitted to hospital with worsening (decompensated) heart failure - You show at least two signs such as weight gain, shortness of breath, leg swelling, or fluid in the lungs You may NOT be eligible if: - You are cardiovascularly unstable or need intravenous medications to support your heart - You need breathing support (BiPAP) - Your kidney function is significantly impaired (creatinine above 250 micromol/L) Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Frusemide will be administered subcutaneously through a Safe - T intima cannula continuously via a Niki syringe driver. Hourly Frusemide dose will be determined by the treating Cardiologist ( 10-20mg/